SAI PARENTERALS

Date: 25.08.2026

To,

The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 (BSE Scrip Code: 544742)	The Manager, NSE Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai- 400051. (NSE Symbol: SAIPARENT)

Dear Sir/Madam,

Unit: Sai Parenterals Limited

Subject: Press Release- Disclosure under Reg. 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled:

Sai Parenterals' Australian Subsidiary, Noumed Pharmaceuticals, Renews its OTC Supply Agreement with one of Australia's Leading Pharmacy Networks in a 3-Year Deal Valued at Australian Dollars (AUD) 30 million (Equivalent to INR 204 crores; 1AUD = INR 68.52)

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Sai Parenterals Limited

ANIL KUMAR KARUSALA
Digitally signed by ANIL KUMAR KARUSALA
Date: 2026.08.25 18:32:35 +05'30'

Mr. Anil Kumar Karusala
Managing Director
(DIN- 01866646)

Encl: As above

Sai Parenterals Limited

Noumed Renews 3-Year OTC Supply Agreement, Valued at AUD 30 Million

Hyderabad, 25th August 2026 – Sai Parenterals Limited, an Integrated CDMO and branded generics enterprise, has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains. The renewal carries an expanded product portfolio, a long agreement tenure and a higher agreement value, and is projected at **AUD 30 million** (approximately INR 204.0 crore; 1 AUD = INR 68) over a **three-year term**, effective immediately.

That translates to about AUD 10 million a year, and the agreement is structured for continuous growth: new product development and line extensions are to be added over its term, steadily widening the portfolio it covers.

Noumed will continue to manage the full value chain — manufacturing, product sourcing, regulatory compliance, TGA registrations, warehousing, quality assurance and nationwide distribution — entrusted to a single accountable partner. Noumed owns the product registrations and holds the marketing authorization, while the pharmacy chain retails the product under its own consumer brand.

The renewal further cements Noumed’s position in the Australian OTC market and confirms the trust placed in its regulatory, quality and supply-chain capabilities in one of the most discerning and tightly regulated markets in the world.

For Sai Parenterals, it improves utilisation of the Group’s regulatory and manufacturing infrastructure, strengthens longer-duration earnings visibility from recurring OTC business, and provides a further platform for expansion into additional regulated international markets.

Together with the 7½-year agreement renewed on 1st July 2026, valued at AUD 202 million (approximately INR 1,300 crore), the Australian OTC book now stands at AUD 232 million of contracted supply, or approximately INR 1,506 crore in aggregate.

Volumes under these agreements are today largely sourced from third-party manufacturers, on which Noumed earns a distribution margin. As the Adelaide facility commissions and Indian capacity expands, that production progressively moves in-house, converting a distribution margin into a manufacturing margin on the same contracted revenue.

This Long-Term Agreement further demonstrates the distinct advantage of our CDMO platform. Beyond securing long-term revenue certainty, this also stands as a testament to our capabilities, and the trust customers place in us.

Commenting on the development, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said:

"Noumed has renewed two supply agreements in the space of two months. Together they take our contracted OTC book in Australia to AUD 232 million, close to INR 1,506 crore in aggregate. These are renewals earned over years of consistent delivery in one of the most tightly regulated markets in the world and they are the reason we acquired the Noumed Platform.

Product under these agreements is today largely sourced from third-party manufacturers, and Noumed earns a distribution margin on it. As our Adelaide facility commissions and our Indian capacity expands, that production moves in-house — the same contracted revenue shall earn at a manufacturing margin rather than a distribution margin."

Mr. Mark Thulborne, Chief Executive Officer, Noumed Pharmaceuticals Pty Ltd, added:

"This renewal reflects the depth of our product range and the confidence our customers place in our ability to supply without interruption. We hold the registrations, we hold the inventory and we shall manage everything from sourcing and regulatory compliance through to nationwide distribution. Our customers value having that entire chain with one accountable partner and they have chosen to extend it.

The agreement is built to grow, with new product development and line extensions to be added over its term. As local manufacturing at Adelaide comes on stream, we will shorten lead times, reduce the inventory we are obliged to carry and serve these partners better than any offshore supply chain allows."

About the Company

Sai Parenterals Limited is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals — contract development and manufacturing for Indian and multinational customers, and branded generic formulations sold domestically and exported into regulated and semi-regulated markets. The Company's portfolio spans 302 commercial products across nine therapeutic areas, supported by 599 approved registrations and 67 dossiers under development, and is manufactured across six facilities, five in India and one in Australia, carrying GMP, WHO-GMP, TGA-Australia and PIC/S accreditations. Through Noumed Pharmaceuticals in Australia and New Zealand, acquired in November 2025, the Company holds one of Australia's largest private-label OTC portfolios, with 15 exclusive long-term supply agreements covering 526 SKUs and a library of over 451 TGA-approved dossiers. More than 50% of consolidated revenue is contracted under long-term regulated-market agreements. The Company completed its initial public offering in March 2026 and was listed on the BSE and the NSE on April 02, 2026.

Safe Harbor

For more information, please contact

Company: **Sai Parenterals Limited**	Investor Relations (IR) **Strategic Growth Advisors Pvt. Ltd.**
CIN: U24231TG2001PLC036043	CIN: U74140MH2010PTC204285
Mr. Anil Kumar, CFO ir@saiparenterals.com saiparenterals.com	Ms. Drashti Shah / Mr. Parin Narichania drashti.shah@sgapl.net / parin.n@sgapl.net +91 87672 24443 / +91 99300 25733 www.sgapl.net